An overview of obesity in children with psychiatric disorders taking atypical antipsychotics.
An overview of obesity in children with psychiatric disorders taking atypical antipsychotics.
复制标题
服用非典型抗精神病药物的精神疾病儿童肥胖概述。
DOI：
10.1080/10673220802073915
复制
发表时间：
2008
影响因子：
3.8
通讯作者：
Noyes,Nancy
中科院分区：
文献类型：
--
作者：
Shin,Lauren;Bregman,Hallie;Frazier,Jean;Noyes,Nancy
背景：患有精神疾病的儿童比普通人群更容易患肥胖症。在某种程度上，这种更大的风险是由于精神药物的使用不断增加。第二代抗精神病药物有效治疗精神疾病，但与体重增加有关。在这个populations.Methods：肥胖，精神疾病和肥胖管理的文章进行了审查。关键词包括儿童，青少年，肥胖，体重增加，精神疾病，治疗，治疗，和antipsychotic.Results：对于儿童肥胖，教育，营养，行为和以家庭为基础的干预措施被确定为非药物干预。所有非药物治疗方式均表明在体重控制或减轻方面取得了中度至中度成功。药物，单独或与饮食和运动，出现有前途的肥胖management.Conclusion：由于有有限的干预研究肥胖儿童精神疾病，一般儿童肥胖的研究可能会参考在这个人群中的试验。这些干预措施的长期有效性和安全性尚不清楚。先前研究的方法学限制包括样本量小，缺乏随机、安慰剂对照和纵向试验，这突出表明需要进一步的试验来解决这些问题。药物引起的肥胖的临床监测和管理仍然是一个重要的公共卫生问题。
Background:Children with psychiatric illness are at greater risk for obesity than those in the general population. In part, this greater risk is due to the escalating use of psychotropic medications. Second-generation antipsychotics effectively treat mental illness but are associated with weight gain. Data for management of obesity in this population is lacking.Methods:Articles on obesity, mental illness, and obesity management were reviewed. Keywords included children, adolescents, obesity, weight gain, psychiatric illness, therapy, treatment, and antipsychotic.Results:For pediatric obesity, educational, nutritional, behavioral, and family-based interventions were identified as nonpharmacological interventions. All nonpharmacological modalities indicate modest to moderate success in weight control or loss. Pharmacological agents, alone or with diet and exercise, appear promising in obesity management.Conclusion:Since there are limited intervention studies available for obese children with psychiatric illness, general childhood obesity studies may be referenced for trials in this population. Long-term efficacy and safety of these interventions are not yet available. Methodological constraints of prior studies include small sample sizes and the absence of randomized, placebo-controlled, and longitudinal trials—highlighting the need for further trials addressing these issues. Clinical monitoring and management of medication-induced obesity remains an important public health concern.